Algorae Pharmaceuticals (ASX:1AI) has won a NSW Health public hospital supply contract, validating the AlgoraeRx commercial strategy with a 3+1+1 year term.
Healthcare Stocks
INOVIQ (ASX:IIQ) has scrapped its 1,200-sample EXO-OC validation study after biobank quality issues, but the ovarian cancer algorithm just improved.
AdAlta (ASX:1AD) closes out its US$1m SHcell obligation as BZDS1901 CAR-T heads to Australian manufacturing and an FDA pre-IND meeting.
Today is the first day of the new financial year, and we think plenty of investors are wondering which ASX Stocks to Buy in FY27. Stocks Down Under recaps 10 stocks that it thinks is set for a good 12 months ahead.
10 ASX Stocks to Buy in FY27
Goodman Group (ASX:GMG)
Goodman enters FY27 with…
Saluda Medical (ASX:SLD) wins FDA approval for its CAP24 surgical paddle lead, opening access to 30% of the US spinal cord stimulation market.
Cann Group (ASX:CAN) is redeeming all Obsidian convertible notes early for US$363,704 net, removing the dilution overhang from its share register.
Neuren Pharmaceuticals (ASX:NEU) could receive US$35 million after first EU commercial sale if DAYBU secures final approval.
KEY POINTS
Recce raised A$4 million from institutions at A$0.40 a share and opened a share purchase plan to raise up to A$4 million more, for a target of up to A$8 million.
Despite the cash and a Middle East licensing plan, the shares fell about 13% (after falling nearly 20% during the…
Skin Elements (ASX:SKN) raises A$900,000 at a 25% discount to fund four product programs, but the dilution math raises hard questions.
4DMedical (ASX:4DX) wins TGA approval for CT VQ in Australia, opening a sixth market and starting the MSAC reimbursement clock.
